1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
Non-melanoma Skin Cancer
University of Alabama at Birminghamprotein_peptidePhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 89/ 100
Competitive context
40 Active assets in the Non-melanoma Skin Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Essen Biotech | Phase 2 | BB |
Multiple Vitamins Injection Women's College Hospital | Phase 3 | BB |
gsk1120212 Cancer Research UK | Phase 2/3 | B |
Dabrafenib Cancer Research UK | Phase 2/3 | B |
Nivolumab H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | B |
View all 50 →
Same molecule, other indications
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →